Anaplastic large cell lymphomas with equivocal DUSP22 FISH results: recommendations for clinical reporting and diagnostic evaluation

DUSP22 FISH 结果不明确的间变性大细胞淋巴瘤:临床报告和诊断评估建议

阅读:1

Abstract

Anaplastic large cell lymphoma (ALCL), one of the most common T-cell lymphomas, shows unifying pathological features but is clinically and genetically heterogeneous. One genetic subgroup, characterized by recurrent DUSP22 rearrangements (R), has distinct morphologic, immunophenotypic, and molecular features and can be identified in routine pathology practice using a breakapart (BAP) fluorescence in situ hybridization (FISH) probe. However, some cases show equivocal BAP-FISH findings (BAP-FISH(EQ)) and the features of these cases are poorly understood. Here, we sought to characterize DUSP22 BAP-FISH(EQ) ALCLs further. First, we applied an immunohistochemistry (IHC) algorithm using TIA1, pSTAT3(Y705), and LEF1, which can predict DUSP22-R with high accuracy. Among 37 BAP-FISH(EQ) ALCLs, 18 (49%) were IHC-algorithm positive (IHC(POS)), 8 (21%) were IHC-algorithm negative (IHC(NEG)), and 11 (30%) were IHC(EQ). In 32 BAP-FISH(EQ) cases, we also applied a dual-color, dual-fusion (D-FISH) probe for t(6;7)(p25.3;q32.3), which accounts for 45% of DUSP22-R ALCLs. Among BAP-FISH(EQ) cases, D-FISH was positive in 10/18 IHC(POS) cases (56%), 0/9 IHC(EQ) cases (0%), and 0/5 IHC(NEG) cases (0%). Median survival in BAP-FISH(EQ) ALCLs was 105 months, intermediate between BAP-FISH(POS) ALCLs (median survival not reached) and BAP-FISH(NEG) ALCLs (19 months). Thus, DUSP22 BAP-FISH(EQ) ALCLs are clinicopathologically heterogeneous, likely due to an admixture of cases with an unbalanced DUSP22-R and cases with focal deletions without rearrangement. For clinical reporting, we recommend that DUSP22 BAP-FISH(EQ) ALCLs be reported as equivocal, and not be grouped with BAP-FISH(POS) ALCLs. Clinical adoption of an IHC algorithm, possibly supplemented by t(6; 7) D-FISH, could facilitate genetic subtyping in about two-thirds of BAP-FISH(EQ) ALCLs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。